shutterstock_1392564812_pavel_kapysh
Pavel Kapysh / Shutterstock.com
23 March 2023Big PharmaLiz Hockley

Amarin launches Fed Circ bid to prove Hikma generic infringed heart drug

Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
23 November 2022   Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.
Generics
6 January 2022   Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.

More on this story

Americas
23 November 2022   Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.
Generics
6 January 2022   Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.

More on this story

Americas
23 November 2022   Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.
Generics
6 January 2022   Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.